EGRX stock forecast
Our latest prediction for Eagle Pharmaceuticals, Inc.'s stock price was made on the Aug. 16, 2017 when the stock price was at 55.77$.
In the short term (2weeks), EGRX's stock price should outperform the market by 2.61%. During that period the price should oscillate between -7.79% and +13.29%.
In the medium term (3months), EGRX's stock price should underperform the market by -0.59%. During that period the price should oscillate between -18.49% and +34.44%.Get email alerts
About Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc. engages in the provision of injectable products. Its products include argatroban, ryanodex, docetaxel injection, non-alcohol formulation and bendeka. The company was founded by Scott L. Tarriff on January 2, 2007 and is headquartered in Woodcliff Lake, NJ.
At the moment the company generates 204M USD in revenues.
On its last earning announcement, the company reported a profit of 1.84$ per share.
The book value per share is 12.34$
Three months stock forecastAug. 16, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|